|
Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer(S1802) |
III |
|
|
A Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a Fusion of FGFR1, FGFR2, or FGFR3 (FUZE) |
II |
|
|
A BioMarker Driven Protocol for Previously Treated ALK-Positive NonSquamous NonSmall Cell Lung Cancer (LU003) |
|
|
|
A Dose Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors (XL184-021) |
I |
|
|
A Double Blind Study of Pembrolizumab+Docetaxel+Prednisone vs Placebo+Docetaxel+Prednisone in Patients with Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer who have Progressed on Next Generation Hormonal Agent (MK3475-921) |
III |
|
|
A Double Blind Trial of Pembrolizumab Plus Enzalutamide vs Placebo Plus Enzalutamide In Patients with Metastatic Castration-Resistant Prostate Cancer (MK3475-641) |
III |
|
|
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated NonSmall Cell Lung Cancer (LUNGMAP) |
|
|
|
A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Ibrutinib in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma(PERSPECTIVE) |
III |
|
|
A Phase I Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody as Monotherapy or in Combination in Patients with Advanced Solid Tumors (CDX1140-01) |
I |
|
|
A Phase I, Study of CDX-1140 a fully human agonist anti-CD40 monoclonal antibody as monotherapy or in combination in patients with advanced solid tumors |
I |
|
|
A Phase I, Study of CDX-1140 a fully human agonist anti-CD40 monoclonal antibody as monotherapy or in combination in patients with advanced solid tumors |
I |
|
|
A Phase I, Study of CDX-1140 a fully human agonist anti-CD40 monoclonal antibody as monotherapy or in combination in patients with advanced solid tumors |
I |
|
|
A Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (LYNK-002) |
II |
|
|
A Randomized Double Blind Study of Adjuvant Immunotherapy with Nivolumab vs Placebo After Complete Resection of Stage IIb/C Melanoma (CA209-76K) |
III |
|
|
A Randomized Double Blind Study of Cabozantinib in Combinaiton with Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced or Metastatic Renal Cell Cancer of Intermediate or Poor Risk (XL184-313) |
III |
|
|
A Randomized Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients wtih Metastatic Castration-Resistant Prostate Cancer (13Y-MC-JPCM) (18128) |
II |
|
|
A Randomized Phase II/III Study of Conventional Chemotherapy Plus or Minus Uproleselan in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (A041701) |
|
|
|
A Randomized Post Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple Negative Breast Cancer following Neo-Adjuvant Chemotherapy (EA1131) |
III |
|
|
A Randomized Study Comparing Two Intermittent Dosing Schedules of Duvelisib In Subjects with Indolent NonHodgkins Lymphoma (VS-0145-229) |
II |
|
|
A Randomized Study Evaluating the Efficacy and Safety of Canakinumab vs Placebo as Adjuvant Therapy in Subjects with Stages II-IIIA and IIIB Completely Resected NonSmall Cell Lung Cancer (17167) |
III |
|
|
A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801) |
II |
|
|
A Randomized Study of First Line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer with Immunobiomarker Signature-Driven Analysis (EA5163) |
|
|
|
A Randomized Study of Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (A041702) |
III |
|
|
A Randomized Study of Nivolumab with Ipilimumab or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1/L1 Agent (S1616) |
II |
|
|
A Randomized STudy of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chonic Myeloid Leukemia; Patients with Molecular Evidence of Disease (S1712) |
II |
|
